(1-ethyl-piperidin-2-yl)-methanol | 30727-20-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (1-ethyl-piperidin-2-yl)-methanol
• 英文别名: (1-ethyl-[2]piperidyl)-methanol；(1-Aethyl-[2]piperidyl)-methanol；1-Aethyl-2-hydroxymethyl-piperidin；1-Ethyl-2-hydroxymethylpiperidin；N-Ethyl-2-hydroxymethylpiperidin；1-Aethyl-piperidin-2-carbinol；(1-Ethylpiperidin-2-yl)methanol
• CAS: 30727-20-9
• 化学式: C₈H₁₇NO
• mdl: MFCD11974861
• 分子量: 143.229
• InChiKey: QDCVURQLJNIQBY-UHFFFAOYSA-N

物化性质

• 沸点：
  87-90 °C(Press: 8 Torr)
• 密度：
  0.932±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium 、 甲苯 、 正丁醇 作用下， 生成 (1-ethyl-piperidin-2-yl)-methanol
  参考文献：
  名称：

  Wakebayashi, 1957, vol. 1, p. 65,68

  摘要：

  DOI：

文献信息

• JAK INHIBITOR
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2108642A1

  公开（公告）日：2009-10-14

  A JAK inhibitor comprising, as an active ingredient, a nitrogen-containing heterocyclic compound represented by formula (I) wherein W represents a nitrogen atom or -CH-; X represents -C (=O) - or -CHR4- (wherein R4 represents a hydrogen atom, or the like); R1 represents the formula described below [wherein Q1 represents-CR8-(wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); Q2 represents -NR15- (wherein R15 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); and R5 and R6 may be the same or different and each represents a hydrogen atom, halogen, carboxy, substituted or unsubstituted lower alkyl, or the like], or the like; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof.

  一种JAK抑制剂，其作为活性成分的是由式(I)表示的含氮杂环化合物 其中W代表氮原子或-CH-; X代表-C(=O)-或-CHR4-(其中R4代表氢原子或类似物); R1代表下述式[其中Q1代表-CR8-(其中R8代表氢原子、取代或未取代的较低烷基或类似物); Q2代表-NR15-(其中R15代表氢原子、取代或未取代的较低烷基或类似物);而R5和R6可以相同也可以不同，每个代表氢原子、卤素、羧基、取代或未取代的较低烷基或类似物，或类似物;而 R2和R3可以相同也可以不同，每个代表氢原子、卤素、取代或未取代的较低烷基或类似物}或其药学上可接受的盐。
• Carbazole-Containing Sulfonamides as Cryptochrome Modulators
  申请人：Reset Therapeutics, Inc.

  公开号：US20130303524A1

  公开（公告）日：2013-11-14

  The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , A, B, C, D, E, F, G, H, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, Cushing's syndrome, and glaucoma.

  本文涉及含有咔唑基磺胺衍生物及其药用可接受盐或水合物的结构式I，其中变量R1、R2、R3、R4、R5、R6、R7、A、B、C、D、E、F、G、H、a和b分别描述。还提供了包含式I化合物的药物组合物，用于治疗Cry介导的疾病或紊乱，如糖尿病、肥胖症、代谢综合征、库欣综合征和青光眼。
• HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS
  申请人：Genentech, Inc.

  公开号：US20160311817A1

  公开（公告）日：2016-10-27

  Compounds of the formula I or a pharmaceutical salt thereof, wherein m, n, q, r, A, W, X 1 , X 2 , X 3 , X 4 , Y, Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

  式I的化合物或其药用盐，其中m、n、q、r、A、W、X1、X2、X3、X4、Y、Z、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10和R11如本文所定义。还公开了制备这些化合物的方法以及将这些化合物用于治疗炎症性疾病如关节炎的方法。
• Methods for treatment of dermatological conditions
  申请人：Wang Bing

  公开号：US20050032751A1

  公开（公告）日：2005-02-10

  A method of reducing the appearance of skin conditions associated with loss of skin tightness, skin firmness, or dark circles under the eyes with topical compositions comprising compounds of any of the Formulae I or Ia as described herein, is disclosed.

  本文揭示了一种通过含有本文所述的任何Formulae I或Ia化合物的局部组合物来减少与皮肤松弛、皮肤紧致度或眼部黑眼圈相关的皮肤状况的方法。
• MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS
  申请人：HADIDA RUAH SARA S.

  公开号：US20090143381A1

  公开（公告）日：2009-06-04

  Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药用可接受的组合物可用作ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节蛋白（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。